Lin Clark
Psychiatric/Mental Health · Murray, UTNPI 1770044570
Payments from drug & device makers
Across 80 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$489
- Neurocrine Biosciences, Inc.$204
- Johnson & Johnson$176
- Vanda Pharmaceuticals Inc.$115
- AbbVie$109
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$106
- plus $288 from 6 others
What the payments were for
- Food & beverage$1,43897%
- Education$493%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 29 | $489 |
| Neurocrine Biosciences, Inc. | 7 | $204 |
| Johnson & Johnson | 10 | $176 |
| Vanda Pharmaceuticals Inc. | 6 | $115 |
| AbbVie | 5 | $109 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $106 |
| Idorsia Pharmaceuticals US Inc | 5 | $79 |
| Alkermes, Inc. | 5 | $75 |
| Lundbeck LLC | 3 | $53 |
| Sunovion Pharmaceuticals Inc. | 3 | $35 |
| Axsome Therapeutics, Inc. | 2 | $32 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
How this compares
$1,486 in reported general payments places this provider in the 70th percentile of 393 psychiatric/mental health providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 14 | $5,129 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 15 | $2,090 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 21 | $1,125 |
| Aripiprazole | 45 | $1,087 |
| Clonazepam | 67 | $808 |
| Quetiapine Fumarate | 37 | $685 |
| Lamotrigine | 40 | $678 |
| Gabapentin | 50 | $622 |
| Trazodone Hcl | 34 | $510 |
| Bupropion XlBupropion Hcl | 17 | $463 |
| Oxcarbazepine | 12 | $430 |
| Pregabalin | 15 | $405 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 15 | $360 |
| Guanfacine Hcl ErGuanfacine Hcl | 21 | $358 |
| Olanzapine | 41 | $334 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Murray
- Karen RischMurray$5K
- Lindsey GavinMurray$4K
- Mallory DanielsonMurray$3K
- Maurice FiedelMurray$3K
- Taylor SublettMurray$3K
- Virginia FischerMurray$3K
- Bret HafenLayton$381K
- Alberto SouzaSaint George$114K
- Anthony BrowningOrem$32K
- Debra HainRiverton$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.